Stock Watch: Robust Diagnostics And Biosimilar Erosion Vie In Roche’s Q2
COVID-19 Testing May Support Roche Longer Than Expected
Roche’s stock price has underperformed in the last nine months in spite of a natural hedge on the strong US dollar that has troubled most other profitable pharma companies. Has Roche become a value stock?
